Suppr超能文献

接受雄激素剥夺治疗的前列腺癌患者的骨骼健康管理。

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

作者信息

Dhanapal Vishnuprabha, Reeves David J

机构信息

Henry Ford Hospital, Detroit, MI 48202, USA.

出版信息

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1.

Abstract

PURPOSE

Patients receiving androgen deprivation therapy undergo a rapid decline in bone mineral density during the first 6 to 12 months of initiating therapy. The World Health Organization has developed and implemented the Fracture Risk Assessment Tool (FRAX) to predict the ten year risk of a major fracture & hip fracture. Additionally, the National Comprehensive Cancer Network and the National Osteoporosis Foundation have developed osteoporosis guidelines. This study aims to characterize the fracture risk (based on the FRAX tool) and the current management of bone health based on national guidelines compliance.

METHODS

A retrospective chart review of patients receiving a LHRH agonist at our institution was conducted. Data collection commenced upon Institutional Review Board approval and included demographics, past medical history, medication regimen, history of androgen deprivation therapy, bone health and its management. The ten year fracture risk calculated with the collected information using the FRAX tool.

RESULTS

A total of 174 subjects included with a mean age of 65.5 years, 71.8% had stage II prostate cancer, 97.7% received the LHRH agonist leuprolide for a mean of 13.8 ± 18.1 months. In addition to ADT, 57% of patients had ≥ 2 risk factors for developing osteoporosis. The risk of sustaining a major fracture increased from 4% to 5.6% after the initiation of ADT (P = <0.001). The risk for sustaining a hip fracture rose from 1.3% to 2.2% (P = <0.001). National guideline compliance was found to be 9%, 5% and 3% respectively for obtaining Dual Energy X-ray Absorptiometry (DEXA) scans, calcium supplementation, and vitamin D supplementation.

CONCLUSION

In addition to predisposing risk factors for osteoporosis, ADT significantly increases the fracture risk in the prostate cancer population. There is room for improvement in the management of bone health as some intervention could have been made in over 90% of patients evaluated.

摘要

目的

接受雄激素剥夺治疗的患者在开始治疗的最初6至12个月内骨矿物质密度会迅速下降。世界卫生组织已开发并实施了骨折风险评估工具(FRAX),以预测十年内发生主要骨折和髋部骨折的风险。此外,美国国立综合癌症网络和美国国家骨质疏松基金会也制定了骨质疏松症指南。本研究旨在基于FRAX工具描述骨折风险,并根据国家指南的依从性描述当前骨骼健康管理情况。

方法

对在我们机构接受促黄体生成素释放激素(LHRH)激动剂治疗的患者进行回顾性病历审查。数据收集在机构审查委员会批准后开始,包括人口统计学、既往病史、药物治疗方案、雄激素剥夺治疗史、骨骼健康及其管理情况。使用收集到的信息通过FRAX工具计算十年骨折风险。

结果

共纳入174名受试者,平均年龄65.5岁,71.8%患有II期前列腺癌,97.7%接受LHRH激动剂亮丙瑞林治疗,平均治疗时间为13.8±18.1个月。除雄激素剥夺治疗外,57%的患者有≥2个发生骨质疏松症的风险因素。开始雄激素剥夺治疗后,发生主要骨折的风险从4%增加到5.6%(P = <0.001)。发生髋部骨折的风险从1.3%升至2.2%(P = <0.001)。在进行双能X线吸收法(DEXA)扫描、补充钙剂和补充维生素D方面,国家指南的依从率分别为9%、5%和3%。

结论

除了存在骨质疏松症的易感风险因素外,雄激素剥夺治疗还显著增加了前列腺癌患者的骨折风险。骨骼健康管理方面有改进空间,因为在超过90%接受评估的患者中本可进行一些干预措施。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验